Table 3.

Results of Electrophysiological Study, Ajmaline Test, and SCN5A Screening

Patient‐Family	1‐a	2‐b	3‐c	4‐c	5‐d	6‐e	7‐f	8‐g	9‐h	10‐h	11‐i	12‐d
HV interval (ms)	54	56	58	54	68	55	52	65	48	66	38	64
Ajmaline dose (%)a	100	80	60	80	60	60	80	100	100	100	100	100
QRS widening (%)b	124	115	169	179	189	147	153	126	107	125	126	106
Drug‐induced BrP	Yes	Yes	Yes	No	No	No	No	No	No	No	No	No
Drug‐induced sVA	No	No	Yes	No	No	No	No	No	No	No	No	No
SCN5A mutation	No	No	No	No	No	No	No	‐	‐	‐	‐	‐

^aResults are given in % of the theoretical dose of ajmaline, based on the recommendations of the Second Consensus Conference on Brugada Syndrome (0.2 mg/kg per min for 5 minutes).

^bResults are given in % of the baseline QRS.

NA = not available.